Terns Pharmaceuticals Current Valuation vs. Price To Book

TERN Stock  USD 6.34  0.46  7.82%   
Based on Terns Pharmaceuticals' profitability indicators, Terns Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Terns Pharmaceuticals' ability to earn profits and add value for shareholders. As of the 29th of November 2024, Price To Sales Ratio is likely to drop to 142.92. In addition to that, EV To Sales is likely to drop to 104.76. At this time, Terns Pharmaceuticals' Net Interest Income is very stable compared to the past year. As of the 29th of November 2024, Interest Income is likely to grow to about 13.5 M, while Accumulated Other Comprehensive Income is likely to drop (19.9 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.390.44
Fairly Down
Slightly volatile
For Terns Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Terns Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Terns Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Terns Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Terns Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
0.035
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Terns Pharmaceuticals Price To Book vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Terns Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Terns Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Terns Pharmaceuticals is rated fourth in current valuation category among its peers. It is rated below average in price to book category among its peers . The ratio of Current Valuation to Price To Book for Terns Pharmaceuticals is about  113,056,068 . As of the 29th of November 2024, Price To Book Ratio is likely to drop to 1.72. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Terns Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Terns Current Valuation vs. Competition

Terns Pharmaceuticals is rated fourth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 1.9 Billion. Terns Pharmaceuticals holds roughly 167.04 Million in current valuation claiming about 9% of equities under Health Care industry.

Terns Price To Book vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Terns Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
167.04 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Terns Pharmaceuticals

P/B

 = 

MV Per Share

BV Per Share

 = 
1.48 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Terns Price To Book Comparison

Terns Pharmaceuticals is currently under evaluation in price to book category among its peers.

Terns Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Terns Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Terns Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Terns Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Terns Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-19 K-19.9 K
Net Interest Income12.9 M13.5 M
Interest Income12.9 M13.5 M
Operating Income-102.6 M-97.4 M
Net Loss-90.2 M-85.7 M
Income Before Tax-90 M-85.5 M
Total Other Income Expense Net12.6 M13.2 M
Net Loss-54.3 M-57 M
Net Loss-90.2 M-85.7 M
Income Tax Expense239 K335.7 K
Non Operating Income Net Other1.8 M1.6 M
Change To Netincome12.4 M13 M
Net Loss(1.27)(1.33)
Income Quality 0.75  0.94 
Net Income Per E B T 1.00  0.80 

Terns Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Terns Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Terns Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Terns Pharmaceuticals' important profitability drivers and their relationship over time.

Use Terns Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Terns Pharmaceuticals Pair Trading

Terns Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Terns Pharmaceuticals position

In addition to having Terns Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run IT Thematic Idea Now

IT
IT Theme
Information Technology (IT) companies and IT service providers across different domains. The IT theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize IT Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:
Check out World Market Map.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
To fully project Terns Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Terns Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Terns Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Terns Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Terns Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Terns Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Terns Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.